Study of a new medicine for children with KCNT1-related epilepsy
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study tests a new medicine (S230815) given by lumbar puncture (spinal tap) to see if it helps reduce seizures in children with a specific genetic cause of epilepsy. It is for children aged 2 to 12 who have not responded well to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 2 and 12 years old.
- Your child must have a confirmed change in the KCNT1 gene and a diagnosis of specific seizure types (migrating focal seizures or early-onset epileptic encephalopathy).
- Your child's current seizure medications or treatments must be stable.
- Your child must not have other gene changes known to cause epilepsy.
- Your child must not have other serious medical conditions, like bleeding disorders, liver problems, or need a breathing tube or tracheostomy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called elsunersen in children with a specific type of epilepsy caused by changes in the SCN2A gene. It aims to see if the drug can reduce seizures and be safe for children.
This study tests a drug called phenylbutyrate for people with seizures caused by SLC6A1 gene changes. The drug may help reduce seizure frequency. The trial is fully remote, so you can join from anywhere in the U.S. without going to a clinic.
This trial tests a new drug called ABS-1230 in children and young adults with KCNT1-related epilepsy, a rare genetic form of epilepsy. The study will check if the drug is safe and if it helps reduce seizures.
This study uses a newer, more detailed type of genetic testing (long-read genome sequencing) to look for the cause of severe childhood epilepsy and developmental delays when standard testing has found nothing. The goal is to find answers for families who have gone without a diagnosis.
This trial tests a medication called LP352 for children and adults with certain types of epilepsy (Dravet syndrome, Lennox-Gastaut syndrome, or other developmental and epileptic encephalopathies). It's for people who already completed a previous study of LP352 and may benefit from continued treatment.
This early-phase study tests how safe ETX101 is and whether it can help reduce seizures in young children with Dravet syndrome caused by an SCN1A gene change. It mainly enrolls infants and children with a specific type of seizure history and genetic result.
Hear when a new Epileptic Encephalopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.